Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone

Leukemia and Lymphoma

Volumn 51, Issue 9, 2010, Pages 1-10

  Hui, David ^a   Proctor, Bradley ^a   Donaldson, Jane ^a   Shenkier, Tamara ^a   Hoskins, Paul ^a   Klasa, Richard ^a   Savage, Kerry ^a   Chhanabhai, Mukesh ^b   Gascoyne, Randy D ^b   Connors, Joseph M ^a   Sehn, Laurie H ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

diffuse large B cell lymphoma; extranodal; Non Hodgkin lymphoma; prognosis; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; ASCITES; BONE MARROW METASTASIS; BONE METASTASIS; CANCER CHEMOTHERAPY; FEMALE; HEAD AND NECK CANCER; HEART METASTASIS; HUMAN; KIDNEY METASTASIS; LARGE CELL LYMPHOMA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MESENTERY; METASTASIS; MULTIVARIATE ANALYSIS; NASOPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN METASTASIS; SOFT TISSUE METASTASIS; SPINE METASTASIS; STOMACH CANCER; TREATMENT OUTCOME;

EID: 77956331404     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.504872     Document Type: Article

References (38)

1. Swerdlow SH, Campo E, Harris N, et al. editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007;21:37-43.
3. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
5. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in british columbia. J Clin Oncol 2005;23:5027-5033.
6. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
7. Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109: 1857-1861.
8. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the united states from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-1251.
9. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-2804.
10. Raghoebier S, Kramer MH, van Krieken JH, et al. Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma. Blood 1991;78:2680-2685.
11. Moller MB, Pedersen NT, Christensen BE. Diffuse large Bcell lymphoma: clinical implications of extranodal versus nodal presentation - a population-based study of 1575 cases. Br J Haematol 2004;124:151-159.
12. Otter R, Gerrits WB, vd Sandt MM, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol 1989;25:1203-1210.
13. Rudders RA, Ross ME, DeLellis RA. Primary extranodal lymphoma: response to treatment and factors influencing prognosis. Cancer 1978;42:406-416.
14. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extranodal sites. Int J Cancer 1997;72:923-930.
15. d'Amore F, Christensen BE, Brincker H, et al. Clinicopathological features and prognostic factors in extranodal non- Hodgkin lymphomas. Danish LYFO study group. Eur J Cancer 1991;27:1201-1208.
16. Gospodarowicz MK, Sutcliffe SB. The extranodal lymphomas. Semin Radiat Oncol 1995;5:281-300.
17. Economopoulos T, Asprou N, Stathakis N, et al. Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics. Leuk Lymphoma 1996;21:131-136.
18. Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003;14:131-139.
19. Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007;18:129-135.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
22. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373-2380.
23. Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the international prognostic index. Blood 2007;110:1278-1282.
24. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006;76:473-480.
25. Sehn LH, Chhanabhai M, Singh S, et al. Both discordant and concordant bone marrow (BM) involvement predict for a poorer outcome independent of the IPI in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Blood 2007;110(Suppl. 1): Abstract 1559.
26. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997;8:727-737.
27. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999;10:1023-1033.
28. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008;19:233-241.
29. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-1288.
30. Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol 2008;65:183-189.
31. Brooks JJ, Enterline HT. Primary gastric lymphomas. A clinicopathologic study of 58 cases with long-term follow-up and literature review. Cancer 1983;51:701-711.
32. Dimopoulos MA, Moulopoulos LA, Costantinides C, Deliveliotis C, Pantazopoulos D, Dimopoulos C. Primary renal lymphoma: a clinical and radiological study. J Urol 1996; 155:1865-1867.
33. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol 2003;27:1538-1545.
34. Hanna E, Wanamaker J, Adelstein D, Tubbs R, Lavertu P. Extranodal lymphomas of the head and neck. A 20-year experience. Arch Otolaryngol Head Neck Surg 1997;123: 1318-1323.
35. Hatano B, Ohshima K, Tsuchiya T, Yamaguchi T, Kawasaki C, Kikuchi M. Clinicopathological features of gastric B-cell lymphoma: a series of 317 cases. Pathol Int 2002;52:677-682.
36. Hughes M, Morrison A, Jackson R. Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma 2005;46:873-877.
37. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
38. Jehan Z, Siraj AK, Abubaker J, et al. Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. Oncology 2008;75:71-80.